Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (+)-halofuginone
2. (+-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone
3. (+-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone Monohydrobromide
4. (-)-halofuginone
5. (-)-halofuginone Hydrobromide
6. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Hydrochloride (1:1), Rel-
7. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-((2s,3r)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Hydrobromide (1:1)
8. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Hydrobromide, Trans-(+-)-
9. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-, Mono(2-hydroxypropanoate)(salt)
10. 6-chloro-7-bromo-(+)-febrifugine
11. 6-chloro-7-bromofebrifugine
12. 7-bromo-6-chloro-3,3-(3-hydroxy-2-piperidyl)acetonyl-4(3h)-quinazolinone-hydrolactate
13. 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
14. 7-bromo-6-chloro-3-(3-((2s,3r)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
15. 7-bromo-6-chloro-3-(3-((2s,3r)-3-hydroxy-2-piperidyl)-2-oxo-propyl)quinazolin-4-one Hydrobromide
16. 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
17. 7-bromo-6-chlorofebrifugine
18. Cebegine
19. Chloro-bromofebrifugine
20. Chlorobromofebrifugine
21. Halagon
22. Halocur
23. Halofuginon
24. Halofuginone
25. Halofuginone Hbr
26. Halofuginone Hcl
27. Halofuginone Hydrobromide
28. Halofuginone Hydrobromide, (-)-
29. Halofuginone Hydrochloride
30. Halofuginone Monohydrobromide
31. Halofuginone Monohydrochloride
32. Halofuginone, (+)-
33. Halofuginone, (-)-
34. Halofunginone
35. Ru 19110
36. Ru-19110
37. Ru19110
38. Stenorol
39. Trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone
1. 82186-71-8
2. Schembl2562822
3. Chembl1162014
4. Ac-30636
5. 7-bromo-6-chloro-3-(3-((2s,3r)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3h)-one 2-hydroxypropanoate
6. 7-bromo-6-chloro-3-[3-[(2s,3r)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;2-hydroxypropanoic Acid
| Molecular Weight | 504.8 g/mol |
|---|---|
| Molecular Formula | C19H23BrClN3O6 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 503.04588 g/mol |
| Monoisotopic Mass | 503.04588 g/mol |
| Topological Polar Surface Area | 140 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 592 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
In newborn calves:
- Prevention of diarrhoea due to diagnosed Cryptosporidium parvum infection, in farms with history of cryptosporidiosis. Administration should start in the first 24 to 48 hours of age.
- Reduction of diarrhoea due to diagnosed Cryptosporidium parvum infection. Administration should start within 24 hours after the onset of diarrhoea. In both cases, the reduction of oocysts excretion has been demonstrated.
Angiogenesis Inhibitors
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. (See all compounds classified as Angiogenesis Inhibitors.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Coccidiostats
Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals. (See all compounds classified as Coccidiostats.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
QP51AX08
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Market Place
ABOUT THIS PAGE
A Halofuginone Lactate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Halofuginone Lactate, including repackagers and relabelers. The FDA regulates Halofuginone Lactate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Halofuginone Lactate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Halofuginone Lactate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Halofuginone Lactate supplier is an individual or a company that provides Halofuginone Lactate active pharmaceutical ingredient (API) or Halofuginone Lactate finished formulations upon request. The Halofuginone Lactate suppliers may include Halofuginone Lactate API manufacturers, exporters, distributors and traders.
click here to find a list of Halofuginone Lactate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Halofuginone Lactate DMF (Drug Master File) is a document detailing the whole manufacturing process of Halofuginone Lactate active pharmaceutical ingredient (API) in detail. Different forms of Halofuginone Lactate DMFs exist exist since differing nations have different regulations, such as Halofuginone Lactate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Halofuginone Lactate DMF submitted to regulatory agencies in the US is known as a USDMF. Halofuginone Lactate USDMF includes data on Halofuginone Lactate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Halofuginone Lactate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Halofuginone Lactate suppliers with USDMF on PharmaCompass.
Halofuginone Lactate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Halofuginone Lactate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Halofuginone Lactate GMP manufacturer or Halofuginone Lactate GMP API supplier for your needs.
A Halofuginone Lactate CoA (Certificate of Analysis) is a formal document that attests to Halofuginone Lactate's compliance with Halofuginone Lactate specifications and serves as a tool for batch-level quality control.
Halofuginone Lactate CoA mostly includes findings from lab analyses of a specific batch. For each Halofuginone Lactate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Halofuginone Lactate may be tested according to a variety of international standards, such as European Pharmacopoeia (Halofuginone Lactate EP), Halofuginone Lactate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Halofuginone Lactate USP).
LOOKING FOR A SUPPLIER?
